Year: 2021

news_6

HighTide Announces First Patient Dosed in Phase 2 PRONTO-PBC Clinical Study Evaluating HTD1801 in Adult Patients with Primary Biliary Cholangitis

SHENZHEN, China & ROCKVILLE, Md.--(BUSINESS WIRE)--HighTide Therapeutics (“HighTide”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for...

news_6

BeiGene Announces First Presentation of the Phase 3 ALPINE Trial Comparing BRUKINSA® (Zanubrutinib) to Ibrutinib in Chronic Lymphocytic Leukemia to Be Featured in Presidential Symposium at EHA2021

BRUKINSA demonstrated superior objective response rate by investigator assessment in the planned interim analysis BRUKINSA was associated with a statistically...